PDCD1 and neoplasm: While trials are underway combining CPIs with denosumab, bispecific antibodies targeting the PD-1/PD-L1 and RANK/RANKL pathways have been developed, and show significant anti-tumor activity in mouse models, in particular those of colon and lung cancer [87].